Radium-223 dichloride (trade name: Xofigo) was approved in November 2013 for the treatment of prostate cancer that has spread to the bones (bone metastases) in men for whom a standard hormone blocker is no longer effective. In September 2018, the approval status was changed. Since then, radium-223 dichloride is only an option for men who have prostate cancer that is progressing despite two previous systemic treatments or for whom systemic treatment is no longer possible.
If prostate cancer is at an advanced stage, the tumor has spread to other parts of the body and complete recovery is no longer possible. Then systemic treatment is used. This means that the treatment has an effect on the whole body. Using medication to block the production of testosterone is one way to slow down the progression of the cancer. If the cancer progresses despite treatment with these hormone blockers, it is referred to as "hormone refractory" or "castration-resistant" metastatic prostate cancer. Other treatments are then often used as well, such as chemotherapy.
Radium-223 dichloride has been approved for use in patients who have bone metastases that are causing symptoms, such as pain.
Radium-223 dichloride is radioactive and collects mostly in the bones. When applied from a nearby source, it is supposed to slow the growth of the bone metastases. If there are metastatic tumors in other organs as well, it shouldn't be used.
Radium-223 dichloride is injected slowly into a vein using a syringe. The exact dose will depend on the patient's body weight. One course of treatment consists of six injections. The injections are given four weeks apart.
Patients who have prostate cancer and bone metastases, and have had at least two previous systemic treatments – or patients for whom systemic treatment is not an option – receive best supportive care (BSC). BSC should be tailored to the patient's individual needs. The aim is to relieve pain and other symptoms, and improve quality of life.
In 2019, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether radium-223 dichloride has any advantages or disadvantages in men who have advanced prostate cancer that is progressing despite previous systemic treatments or in men who can't have systemic treatment. The manufacturer didn't provide any suitable data with which to answer this question.
This information summarizes the main results of a review produced by the Institute for Quality and Efficiency in Health Care (IQWiG, Germany). The review was commissioned by the German Federal Joint Committee (G-BA) as part of the “early benefit assessment of medications.” On the basis of the review and the hearings received, the G-BA passed a resolution on the added benefit of radium-223 dichloride (Xofigo).
Institute for Quality and Efficiency in Health Care (IQWiG, Germany). Radium-223 dichloride (mCRPC) – Benefit assessment according to §35a Social Code Book V. Dossier assessment; Commission A19-32. July 11, 2019. (IQWiG reports; Volume 791).
IQWiG health information is written with the aim of helping
people understand the advantages and disadvantages of the main treatment options and health
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.